Previous 10 | Next 10 |
2023-06-21 10:07:44 ET Gainers: Ocean Biomedical ( OCEA ) +43% . PetVivo Holdings ( PETV ) +23% . Patterson Companies ( PDCO ) +14% . Zentalis Pharmaceuticals ( ZNTL ) +5% . RenovoRx ( RNXT ) +4% . Losers: uniQure ( ...
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that CEO Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Jefferies Healthcare Conf...
2023-05-31 05:55:18 ET Summary Gain Therapeutics is a biotechnology company focused on drug development powered by its SEE-Tx™ target identification platform, which identifies and optimizes binding sites on biological targets that have never before been targeted. The compan...
CAMBRIDGE, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, presented data today validating the ability of novel capsids generated through its TRACER™ capsid...
2023-05-09 16:56:05 ET Voyager Therapeutics, Inc. (VYGR) Q1 2023 Results Conference Call May 09, 2023 08:30 AM ET Company Participants Pete Pfreundschuh - Chief Financial Officer Dr. Al Sandrock - Chief Executive Officer Dr. Todd Carter - Chief Scientific Officer...
2023-05-09 13:22:40 ET Gainers: TScan Therapeutics ( TCRX ) +124% . Shengfeng Development Limited ( SFWL ) +102% . Mobiquity Technologies ( MOBQ ) +68% . ClearOne ( CLRO ) +62% . U.S. GoldMining ( USGOW ) +57% . Novavax ( N...
2023-05-09 07:10:23 ET Voyager Therapeutics press release ( NASDAQ: VYGR ): Q1 GAAP EPS of $2.94 beats by $1.90 . Revenue of $150.48M (+22700.0% Y/Y) beats by $97.98M . Cash, cash equivalents and marketable securities as of March 31, 2023, were $273.3 million. ...
- Neurocrine Biosciences strategic collaboration and Novartis license option exercise demonstrate Voyager pipeline and platform value and strengthen balance sheet - - Alzheimer’s disease franchise advances: selected lead candidate for anti-tau antibody program; IND submission on ...
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of George Scangos, Ph.D., to its Board of Directors. Scangos has decades...
2023-05-08 12:45:05 ET Voyager Therapeutics ( NASDAQ: VYGR ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is $1.26 (+325.0% Y/Y) and the consensus Revenue Estimate is $52.5M (+7400.0% Y/Y). Over the la...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...